{\rtf1\deflang1033\deflangfe1033\margl720\margr720\margt360\margb360{\stylesheet{\fs20\lang1033\snext0 Normal;}
{\s1\sb240\keepn{\*\pn \pnlvl1\pndec\pnprev1\pnstart1\pnsp144}\b\f0\fs30\lang1033 \sbasedon0\snext0 heading 1;}
{\s2\sb200\keepn{\*\pn \pnlvl2\pndec\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs26\lang1033 \sbasedon0\snext0 heading 2;}
{\s3\sb180\keepn{\*\pn \pnlvl3\pndec\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs22\lang1033 \sbasedon0\snext0 heading 3;}
{\s4\sb160\keepn{\*\pn \pnlvl4\pnucltr\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs22\lang1033 \sbasedon0\snext0 heading 4;}
{\s5\sb140\keepn{\*\pn \pnlvl5\pncltr\pnprev1\pnstart1\pnsp144}\b\f0\fs20\lang1033 \sbasedon0\snext0 heading 5;}
{\s6\tqc\lang1033\sbasedon0\snext6 footer;}
{\*\cs16 \additive\super\sbasedon10 footnote reference;}
{\*\cs18 \additive\sbasedon10 page number;}}
{\fonttbl{\f0\fnil Times New Roman;}{\f1\fnil Courier New}{\f2005\fnil Courier New;}{\f2010\fnil Wingdings;}{\f2020\fnil Webdings;}{\f2\fnil Arial;}{\f3\fnil Arial;}{\f4\fnil LucidaHandwriting;}{\f5\fnil Symbol;}{\f6\fnil Symbol;}{\f7\fnil Ferdsch;}{\f30\fnil Myriad Cn Semibold;}{\f31\fnil Myriad Roman;}{\f50\fnil Courier New;}{\f51\fnil Times New Roman;}{\f52\fnil Arial;}{\f53\fnil Symbol;}{\f54\fnil Wingdings;}{\f55\fnil Wingdings 2;}{\f56\fnil Wingdings 3;}{\f57\fnil Webdings;}{\f58\fnil Arial Narrow;}{\f59\fnil Arial Unicode MS;}{\f60\fnil Cyberbit;}{\f61\fnil Morningstar 1U Light;}{\f62\fnil Calibri;}}
{\colortbl;\red0\green0\blue0;\red127\green0\blue0;\red0\green0\blue255;\red127\green127\blue127;\red0\green51\blue153;\red255\green204\blue0;\red255\green255\blue255;\red246\green244\blue236;\red0\green0\blue0;\red153\green153\blue153;}
{\*\bkmkstart filing_1}{\*\bkmkend filing_1}{\*\bkmkstart doc_1_1}{\*\bkmkend doc_1_1}\par\pard\plain\brdrb\brdrs\cf1\f51\fs20\ql \~\par\pard\plain\brdrb\brdrs\sa44\cf1\f51\fs20\ql \~\par\pard\plain\sb264\cf1\f51\fs36\b\qc UNITED STATES\par\pard\plain\cf1\f51\fs36\b\qc SECURITIES AND EXCHANGE COMMISSION\par\pard\plain\cf1\f51\fs24\b\qc Washington, D.C. 20549\par\pard\plain\cf1\f51\fs12\ql \~\par\pard\plain\brdrb\brdrs\sa44\cf1\f51\fs20\ql \~\par\pard\plain\sb132\cf1\f51\fs36\b\qc FORM 6-K\par\pard\plain\cf1\f51\fs12\ql \~\par\pard\plain\brdrb\brdrs\sa44\cf1\f51\fs20\ql \~\par\pard\plain\sb132\cf1\f51\fs24\b\qc Report of Foreign Private Issuer\par\pard\plain\cf1\f51\fs24\b\qc Pursuant to Rule 13a-16 or 15d-16\par\pard\plain\cf1\f51\fs24\b\qc Under the Securities Exchange Act of 1934\par\pard\plain\sb264\cf1\f51\fs24\b\qc For the month of August, 2018\par\pard\plain\sb264\cf1\f51\fs24\b\qc Commission File Number 001-38079\par\pard\plain\cf1\f51\fs12\ql \~\par\pard\plain\brdrb\brdrs\sa44\cf1\f51\fs20\ql \~\par\pard\plain\sb132\cf1\f51\fs48\b\qc UROGEN PHARMA LTD.\par\pard\plain\cf1\f51\fs20\b\qc (Translation of registrant\u8217?s name into English)\par\pard\plain\cf1\f51\fs24\ql \~\par\pard\plain\brdrb\brdrs\sa44\cf1\f51\fs20\ql \~\par\pard\plain\sb132\cf1\f51\fs20\b\qc 9 Ha\u8217?Ta\u8217?asiya Street\par\pard\plain\cf1\f51\fs20\b\qc Ra\u8217?anana 4365007, Israel\par\pard\plain\cf1\f51\fs16\b\qc (Address of principal executive offices)\par\pard\plain\cf1\f51\fs12\ql \~\par\pard\plain\brdrb\brdrs\sa44\cf1\f51\fs20\ql \~\par\pard\plain\sb132\cf1\f51\fs20\ql Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.\par\pard\plain\sb264\cf1\f51\fs20\qc Form 20-F\~\~\u9746?\~\~\~\~Form 40-F\~\~\u9744?\par\pard\plain\sb264\cf1\f51\fs20\ql Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule\plain\cf1\f51\fs20\ql 101(b)(1):\~\~\u9744?\par\pard\plain\sb264\cf1\f51\fs20\ql Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule\plain\cf1\f51\fs20\ql 101(b)(7):\~\~\u9744?\par\pard\plain\cf1\f51\fs24\ql \~\par\pard\plain\brdrb\brdrs\cf1\f51\fs20\ql \~\par\pard\plain\brdrb\brdrs\sa44\cf1\f51\fs20\ql \~
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\brdrb\brdrs\sa44\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql On August\~8, 2018, UroGen Pharma Ltd. issued a press release, a copy of which is furnished as Exhibit 99.1 to this Form\~6-K.\par\pard\plain\cf1\f51\fs24\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx609\clvertalb\cellx1135\clvertalc\cellx10800\trrh66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx609\clvertalb\cellx1135\clvertalc\cellx10800\trrh66\row}}}
{\trowd\clvertalb\cellx609\clvertalb\cellx1135\clvertalb\cellx10800\trrh243
\pard\plain\intbl\brdrb\brdrs\cf1\f51\fs16\b\qc Exhibits\cell\pard\plain\intbl\cf1\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs16\ql \~\cell{
{\trowd\clvertalb\cellx609\clvertalb\cellx1135\clvertalb\cellx10800\trrh243\row}}}
{\trowd\clvertalc\cellx609\clvertalc\cellx10799\trrh66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx609\clvertalc\cellx10799\trrh66\row}}}
{\trowd\cellx609\clvertalb\cellx1135\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql 99.1\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs20\ql Press Release, dated August 8, 2018: UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer.\cell{
{\trowd\cellx609\clvertalb\cellx1135\cellx10800\trrh248\row}}}
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par{\*\bkmkstart part_1_2_1}{\*\bkmkend part_1_2_1}\pard\plain\cf1\f51\fs20\b\qc SIGNATURES\par\pard\plain\sb264\cf1\f51\fs20\ql Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on\plain\cf1\f51\fs20\ql its behalf by the undersigned, thereunto duly authorized.\par\pard\plain\cf1\f51\fs24\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx4823\clvertalb\cellx4929\clvertalc\cellx5346\clvertalb\cellx5416\clvertalc\cellx5745\clvertalb\cellx6074\clvertalc\cellx10800\trrh66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx4823\clvertalb\cellx4929\clvertalc\cellx5346\clvertalb\cellx5416\clvertalc\cellx5745\clvertalb\cellx6074\clvertalc\cellx10800\trrh66\row}}}
{\trowd\cellx4823\clvertalb\cellx4929\cellx5346\clvertalb\cellx5416\cellx10798\trrh248
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\b\ql UROGEN PHARMA LTD.\cell{
{\trowd\cellx4823\clvertalb\cellx4929\cellx5346\clvertalb\cellx5416\cellx10798\trrh248\row}}}
{\trowd\clvertalc\cellx4823\clvertalc\cellx5346\clvertalc\cellx5745\clvertalc\cellx10797\trrh66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx4823\clvertalc\cellx5346\clvertalc\cellx5745\clvertalc\cellx10797\trrh66\row}}}
{\trowd\cellx4823\clvertalb\cellx4929\cellx5346\clvertalb\cellx5416\cellx5745\clvertalb\cellx6074\clvertalb\cellx10800\trrh309
\pard\plain\intbl\cf1\f51\fs20\ql August\~8, 2018\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql By:\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\brdrb\brdrs\sa22\cf1\f51\fs20\ql /s/ Ron Bentsur\cell{
{\trowd\cellx4823\clvertalb\cellx4929\cellx5346\clvertalb\cellx5416\cellx5745\clvertalb\cellx6074\clvertalb\cellx10800\trrh309\row}}}
{\trowd\cellx4823\clvertalb\cellx4929\cellx5346\clvertalb\cellx5416\cellx5745\clvertalb\cellx6074\clvertalb\cellx10800\trrh248
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql Ron Bentsur\cell{
{\trowd\cellx4823\clvertalb\cellx4929\cellx5346\clvertalb\cellx5416\cellx5745\clvertalb\cellx6074\clvertalb\cellx10800\trrh248\row}}}
{\trowd\cellx4823\clvertalb\cellx4929\clvertalb\cellx5346\clvertalb\cellx5416\cellx5745\clvertalb\cellx6074\clvertalb\cellx10800\trrh248
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql Chief Executive Officer\cell{
{\trowd\cellx4823\clvertalb\cellx4929\clvertalb\cellx5346\clvertalb\cellx5416\cellx5745\clvertalb\cellx6074\clvertalb\cellx10800\trrh248\row}}}
\page{\*\bkmkstart doc_1_2}{\*\bkmkend doc_1_2}\pard\plain\cf1\f51\fs20\b\qr Exhibit 99.1\par\pard\plain\cf1\f51\fs24\ql \~\par\ql{\*\shppict{\pict\pngblip\picw150\pich53\picscalex75\picscaley75\bliptag-482388779
{\*\blipuid fdfbe54a1a61703a6d64bb97ec397e76}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}}
\par\pard\plain\sb264\cf1\f51\fs20\b\qc UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer\par\pard\plain\sb264\cf1\f51\fs20\i\qc Life Sciences Veteran Brings Extensive Global Finance, Commercial Operations and Business Development Experience to\plain\cf1\f51\fs20\i\qc Prepare UroGen for its Transition from a Clinical Stage Company to Commercialization\par\pard\plain\sb264\cf1\f51\fs20\ql RA\u8217?ANANA, Israel, and NEW YORK, August\~08, 2018 \u8212? UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage\plain\cf1\f51\fs20\ql biopharmaceutical company today announced that Peter P. Pfreundschuh has been appointed as Chief Financial Officer (CFO)\plain\cf1\f51\fs20\ql effective August\~20, 2018. Mr.\~Pfreundschuh brings to UroGen more than two decades of executive leadership experience in life\plain\cf1\f51\fs20\ql sciences. Stephen Mullennix, who has served as UroGen\u8217?s Interim CFO since June 2018, will continue in his role as the\plain\cf1\f51\fs20\ql Company\u8217?s Chief Operating Officer (COO).\par\pard\plain\sb264\cf1\f51\fs20\ql \u8220?The addition of Peter to our executive team will be instrumental as we prepare for potential approval and\plain\cf1\f51\fs20\ql commercialization of our first therapy in the U.S.,\u8221? said Ron Bentsur, Chief Executive Officer of UroGen. \u8220?The\plain\cf1\f51\fs20\ql depth and breadth of Peter\u8217?s experience in biotechnology across global finance, commercial operations and business\plain\cf1\f51\fs20\ql development will be invaluable in our next phase.\u8221?\par\pard\plain\sb264\cf1\f51\fs20\ql \u8220?I\u8217?m excited to join this dynamic team during a pivotal time for the company as it executes on its strategic vision\plain\cf1\f51\fs20\ql of bringing disruptive therapies to patients in areas of unmet need,\u8221? said Mr.\~Pfreundschuh. \u8220?I look forward to\plain\cf1\f51\fs20\ql leading the finance organization and driving long-term shareholder value, particularly as the Company prepares for key\plain\cf1\f51\fs20\ql milestones, including the potential commercialization of its lead product, UGN-101.\u8221?\par\pard\plain\sb264\cf1\f51\fs20\ql Mr.\~Pfreundschuh previously served as the CFO of Sucampo Pharmaceuticals, Inc. where he played a critical role in its recent\plain\cf1\f51\fs20\ql acquisition by Mallinckrodt for $1.2 Billion in February 2018. Prior to joining Sucampo, he was Executive Vice President of\plain\cf1\f51\fs20\ql Finance and CFO of Immunomedics Inc., a late-stage biopharmaceutical company focused on development of therapeutic agents\plain\cf1\f51\fs20\ql in areas of oncology and immunology. Before this, Mr.\~Pfreundschuh was CFO for CircuLite, Inc., a global medical device\plain\cf1\f51\fs20\ql company that was sold in 2013. His previous roles include leadership positions in finance, commercial operations and business\plain\cf1\f51\fs20\ql development within the pharmaceutical industry at AstraZeneca Pharmaceuticals LP, and Johnson\~& Johnson. Mr.\~Pfreundschuh is\plain\cf1\f51\fs20\ql currently a board member of Speratus Therapeutics, Inc., and GitBasic LLC. He has also previously served as an advisor or\plain\cf1\f51\fs20\ql board member to Immunomedics Inc., CircuLite Inc., and Reproductive Medical Associates of New Jersey, in addition to other\plain\cf1\f51\fs20\ql companies and private organizations. He holds a B.S. degree in accounting from Rutgers University School of Business, an\plain\cf1\f51\fs20\ql M.B.A in Finance from Rider University Graduate School of Business, and completed Masters coursework in Strategic Marketing\plain\cf1\f51\fs20\ql for the Healthcare Industry at Northwestern University\u8217?s Kellogg School of Management. Mr.\~Pfreundschuh is a Certified\plain\cf1\f51\fs20\ql Public Accountant (CPA) licensed in the State of New Jersey, and started his career with Ernst\~& Young LLP.\par\pard\plain\sb396\cf1\f51\fs20\b\ql About UroGen Pharma Ltd.\par\pard\plain\sb132\cf1\f51\fs20\ql UroGen Pharma Ltd.\~(Nasdaq:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical\plain\cf1\f51\fs20\ql treatments to address unmet needs in the field of urology,
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\cf1\f51\fs20\ql with a focus on uro-oncology. The Company has developed RTGel\u8482?, a proprietary sustained release, hydrogel-based\plain\cf1\f51\fs20\ql platform technology that has the potential to improve therapeutic profiles of existing drugs.\~UroGen Pharma\u8217?s\~sustained\plain\cf1\f51\fs20\ql release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a\plain\cf1\f51\fs20\ql potentially more effective treatment option.\~UroGen Pharma\u8217?s\~lead product candidates, UGN-101 (MitoGel\u8482?, also\plain\cf1\f51\fs20\ql known as mitomycin urothelial gel) and UGN-102 (VesiGel\u8482?, also known as mitomycin intravesical gel), are designed to\plain\cf1\f51\fs20\ql potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including\plain\cf1\f51\fs20\ql low-grade upper tract urothelial carcinoma and bladder cancer, respectively.\~UroGen Pharma\~is headquartered in\plain\cf1\f51\fs20\ql Ra\u8217?anana,\~Israel\~with U.S. headquarters in\~New York.\par\pard\plain\sb396\cf1\f51\fs20\b\ql Forward Looking Statements\par\pard\plain\sb132\cf1\f51\fs20\ql This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of\plain\cf1\f51\fs20\ql 1995, including with respect to regulatory approval and commercial prospects of the product candidates in UroGen\plain\cf1\f51\fs20\ql Pharma\u8217?s pipeline, including UGN-101 (MitoGel) and the effects of Mr.\~Pfreundschuh joining UroGen Pharma, which\plain\cf1\f51\fs20\ql statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the timing and success of\plain\cf1\f51\fs20\ql clinical trials and potential complications thereof; the ability to obtain and maintain regulatory approval; the labeling for any\plain\cf1\f51\fs20\ql approved product; the scope, progress and expansion of developing and commercializing UroGen Pharma\u8217?s product\plain\cf1\f51\fs20\ql candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-\u224?-vis\plain\cf1\f51\fs20\ql alternative therapies; and UroGen Pharma\u8217?s ability to attract or retain key management, members of the board of directors\plain\cf1\f51\fs20\ql and personnel. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors\plain\cf1\f51\fs20\ql section of the final prospectus for UroGen Pharma\u8217?s public offering of securities in\~the United States\~filed with\plain\cf1\f51\fs20\ql the\~SEC\~on\~January 22, 2018\~and other filings that\~UroGen Pharma\~makes with the\~SEC\~from time to time (which are available\plain\cf1\f51\fs20\ql at\~\plain\cf1\f51\fs20\ul\ql http://www.sec.gov\plain\cf1\f51\fs20\ql ), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen\plain\cf1\f51\fs20\ql Pharma\u8217?s actual results could differ materially and adversely from those anticipated or implied thereby. Any\plain\cf1\f51\fs20\ql forward-looking statements speak only as of the date of this press release and are based on information available to\~UroGen\plain\cf1\f51\fs20\ql Pharma\~as of the date of this release.\par\pard\plain\sb264\cf1\f51\fs20\qc # # #\par\pard\plain\sb396\cf1\f51\fs20\b\ql UROGEN CONTACT:\par\pard\plain\sb132\cf1\f51\fs20\ql Kate Bechtold\par\pard\plain\cf1\f51\fs20\ql Director, Corporate Communications\~& Investor Relations\par\pard\plain\cf1\f51\fs20\ql KateB@urogen.com\par\pard\plain\cf1\f51\fs20\ql 914-552-0456}